Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Uterine Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00622973 2011-10-12

USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

Insel Gruppe AG, University Hospital Bern

Phase 3 Completed
130 enrolled
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡